HER2 testing across practices—Have we come to a consensus on the ideal method of testing? A systematic literature review. Issue 6 (12th May 2020)

• Record Type: Journal Article
• Authors: Nassar, Aziza; Pooja, Advani; Chivukula, Mamatha
• Is Part Of: Breast journal. Volume 26:Issue 6(2020)
• Page Start: 1185
• Page End: 1188
• Publication Date: 2020-05-12
• Subjects: FISH -- HER2 -- immunohistochemistry -- trastuzumab; Breast -- Diseases -- Periodicals; Breast -- Cancer -- Periodicals; 618.19
• DOI: 10.1111/tbj.13867
• Languages: English
• ISSNs: 1075-122X

Abstract

Abstract: Human epidermal growth factor (HER2) is an oncogene that codes for HER2 protein. The gene is amplified, and protein is overexpressed in 20% of patients and carries a poor prognosis. HER2‐positive tumors tend to be more aggressive and highly proliferative. In 2006, trastuzumab, a monoclonal antibody targeting HER2, was approved for use with chemotherapy as an adjuvant treatment for women with HER2‐positive breast cancer. The drug has shown improved survival rates for women with HER2‐positive breast cancer. As promised for survival in HER2‐positive patients continues with new research, and as novel drug approvals emerge, HER2 assessment plays a significant role in adjuvant and in metastatic setting. HER2 assays approved by the US Food and Drug administration include immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and bright field dual in situ hybridization (DISH). Accuracy of HER2 testing across laboratories has an impact on treatment as false‐negative testing can deprive the patients of trastuzumab therapy. The current review will focus on the variability of HER2 testing across laboratories and the potential impact on treatment.